Cystic Fibrosis Clinical Trial
Official title:
Cross Transmissions of Pseudomonas Aeruginosa in a Pediatric Cohort Followed-up at the Cystic Fibrosis Reference Center of the Queen Fabiola Children's University Hospital.
Cystic fibrosis is the most common hereditary autosomal recessive disease in the Caucasian
population. The diseases is caused by a mutation of the gene coding for the CFTR protein
(Cystic fibrosis transmembrane conductance regulator), an ion channel present at the apical
pole of the epithelial cells. The channel dysfunction induces a deficit in hydration and a
hyperviscosity of different exocrine secretions.
Clinically, Cystic fibrosis is a multi-systemic disease. Pulmonary and pancreatic involvement
are classically in the foreground. Degradation of respiratory function, associated with acute
and chronic infections, represents the major cause of morbidity and mortality.
Pseudomonas aeruginosa is a ubiquitous gram-negative bacillus found primarily in stagnant
water. Pseudomonas aeruginosa is capable of colonizing the digestive, pulmonary and urinary
mucosa and the skin. This bacterium is incriminated in many opportunistic infections
including respiratory infections in patients with cystic fibrosis. Pseudomonas aeruginosa
infection is the most common parenchymal lung infection in the Cystic fibrosis community.
Pseudomonas aeruginosa chronic carriage represents a factor of poor prognosis associated with
an increase in morbidity and mortality. Complications related to chronic carriage of
Pseudomonas aeruginosa justify the implementation of strategies of eviction, screening and
eradication of acute Pseudomonas aeruginosa infection.
In addition to Pseudomonas aeruginosa contamination of patients via the environment, hand and
airborne infections between patients with Cystic fibrosis have been reported. Measures to
eliminate cross-transmissions have therefore been implemented in a majority of hospitals.
The aim of the study is firstly to identify the number of Pseudomonas aeruginosa
cross-transmissions between patients with Cystic fibrosis followed-up in Cystic fibrosis
center of HUDERF. Investigator will use the Pulsed-Field Gel Electrophoresis to assess the
possibility of cross-infection.
Depending on the results, Investigator will implement new strategies to avoid future
cross-contamination in our different places of care (consultation, hospitalization,
physiotherapy…).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |